Business Context and Reporting Period
MaxCyte, Inc. (MXCT) is a global life sciences company focused on cell engineering technology for cell and gene therapies. This Form 10-Q covers the quarterly period ended March 31, 2025. The company operates as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $10.39 million | $11.34 million |
| Gross Profit | $8.89 million | $9.94 million |
| Gross Margin | 86% | 88% |
| Net Loss | $(10.26) million | $(9.53) million |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.09) |
| Cash and Cash Equivalents | $23.39 million | $22.25 million |
| Total Investments (Short & Long-term) | $151.31 million | $162.38 million |
| Operating Cash Flow | $(14.41) million | $(10.56) million |
| Accumulated Deficit | $(227.11) million | $(185.32) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 8% year-over-year, driven primarily by a 32% drop in Strategic Platform License (SPL) program-related revenue due to variability in customer milestone achievements. Core revenue (instruments, PAs, licenses, services) increased slightly by 1%.
- Expense Fluctuations:
- R&D: Decreased 12% to $5.90 million, largely due to a one-time severance charge in the prior year and lower lab expenses.
- Sales & Marketing: Decreased 23% to $5.70 million, attributed to headcount reductions and lower travel/professional fees.
- G&A: Increased 20% to $8.53 million, primarily due to $1.2 million in legal and professional fees associated with the SeQure acquisition.
- Acquisition Activity: On January 29, 2025, MaxCyte acquired SeQure, Dx Inc. for a preliminary purchase price of $2.31 million. This added $3.92 million in goodwill and $0.51 million in intangible assets to the balance sheet.
- Interest Income: Decreased 26% to $2.03 million due to lower interest rates and reduced average cash balances.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next 12 months. The company has no debt obligations.
- Strategic Growth: The acquisition of SeQure is expected to expand service offerings for cell therapy developers. The company signed a new SPL agreement with TG Therapeutics in Q1 2025.
- Revenue Volatility: Management expects program-related revenue to remain variable as it depends on partners achieving clinical and regulatory milestones. Long-term revenue growth is anticipated as the installed base of SPL partners matures.
- Contingent Consideration: The SeQure acquisition includes a contingent payment of up to $2.5 million if specific revenue targets are met in 2025 and 2026. The fair value was deemed de minimis at acquisition.
- Risks: Key risks include the ability to raise additional capital if needed, dependence on the success of partners' clinical programs, and competition in the non-viral delivery market.
Investor Verification Checklist
- Verify the sustainability of the 1% core revenue growth amidst the 32% decline in milestone-based revenue.
- Monitor the integration progress of SeQure and the realization of synergies in the coming quarters.
- Assess the impact of the $1.2 million in acquisition-related G&A expenses on future profitability.
- Review the burn rate relative to the $174.7 million in total liquid assets (cash + investments) to confirm the 12-month runway assertion.
- Track the achievement of revenue targets by SeQure that would trigger the $2.5 million contingent payment.